Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron/Bayer Announce Positive VEGF Trap-Eye Data In A Second Eye Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

Application to treat central retinal vein occlusion may be in the works to follow soon after wet AMD filing set for first half of 2011.
Advertisement

Related Content

Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year
Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year
Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year
Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year
Regeneron/Bayer Bullish On Wet-AMD Drug But Commercial Success Is No Guarantee
Regeneron/Bayer Bullish On Wet-AMD Drug But Commercial Success Is No Guarantee

Topics

Advertisement
UsernamePublicRestriction

Register

PS071638

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel